Aptar Pharma is pleased to announce the co-organization and its diamond sponsorship of the third Respiratory Drug Delivery (RDD®) Asia scientific conference, which will welcome internationally renowned speakers in pulmonary and nasal drug delivery. The conference will be held at the Grand Hyatt Kochi hotel from November 14th-16th in Kerala, India.

Mobilizing the respiratory world in Asia

Building on the successes of previous RDD conferences in the U.S., Europe and Asia, RDD Asia 2018 is recognized as one of the premium international meetings in the area. Coorganized with RDD Online, the RDD Asia 2018 conference seeks to connect industrial and academic scientists, clinicians, regulators and business professionals in Asia with their international counterparts, to collectively advance patient treatments in inhaled and nasal drug delivery.

RDD Asia 2018 presenters will summarize recent developments and trends as well as offer their expert insights to stimulate new thinking and ideas amongst attendees. More than 200 delegates from Asia and beyond are expected to attend.

This stimulating scientific environment helps serve as a bridge to foster support for academic collaboration, international regulatory harmonization and commercial developments across continents.

Aptar Pharma leading the way in decoding FDA guidance on Combination Products

In addition to co-organizing the conference and exhibiting, Aptar Pharma will host an interactive workshop on Thursday 15th November addressing the most recent FDA guidance on Combination Products, with a focus on respiratory and nasal drug products. The seminar, entitled “Decoding FDA’s Recent Combination Drug Product Guidance: Applications to DPIs, pMDIs, and Nasal Sprays,” will be presented by Badre Hammond, Associate Director, Market Development at Aptar Pharma.

This workshop will give insights into optimal approaches to help secure approval in this changing and challenging regulatory landscape. It will review various topics, including the definition of combination products, NDA/ANDA submissions, regulatory pathway review, Human Factor studies in the context of combination products, and clarify expectations on the sponsor, the device supplier and regulators.

Aptar Pharma’s informative workshop will take place three times on Thursday, November 15th, ensuring delegates have the greatest opportunity to attend their preferred time slot.

Furthermore, as part of the RDD Asia 2018 scientific conference, Dr. Gerallt Williams, Director of Scientific Affairs at Aptar Pharma, will present a poster entitled “Interpretation Of Manual Actuation Profiles From Nasal Bi-dose Spray Devices”, which demonstrates their impact on analytical and regulatory requirements.

To connect with Aptar Pharma at RDD Asia 2018 and meet their team of experts, register at:
www.rddonline.com/rdd/reg.php?id=16